Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515021 · ClinicalTrials.gov registry record · Phase 4
Diurnal Variation of Plasminogen Activator Inhibitor-1
A Phase 4 study of Metabolic Syndrome X, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00515021 is a Phase 4 study of Metabolic Syndrome X that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 21 participants, below the 71-participant average among 10 other Metabolic Syndrome X trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00515021, a Phase 4 study of Metabolic Syndrome X, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
Conditions Studied
Interventions
- DRUG Eplerenone (Morning)
- DRUG Eplerenone (Night-time)
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515021
The ClinicalTrials.gov registry entry for NCT00515021 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 10 other Metabolic Syndrome X trials with a reported enrollment target (70% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolic Syndrome X appearing as the primary indexed condition, and to 2 interventions - of which Eplerenone (Morning) is the first listed.
NCT00515021 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00515021 about?
NCT00515021 is a clinical study titled "Diurnal Variation of Plasminogen Activator Inhibitor-1". To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
What is the current status of trial NCT00515021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2007-04. Estimated completion is 2010-04.
What conditions does trial NCT00515021 study?
This clinical trial studies the following conditions: Metabolic Syndrome X.
What interventions are being tested in trial NCT00515021?
The interventions under investigation include: Eplerenone (Morning) (DRUG), Eplerenone (Night-time) (DRUG).
Who is sponsoring clinical trial NCT00515021?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00515021 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome X
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
COMPLETED · Phase 4
-
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
COMPLETED · Phase 4
-
Oral Contraceptives in the Metabolic Syndrome
COMPLETED · Phase 4
-
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
COMPLETED · Phase 4
-
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
COMPLETED · Phase 2
-
Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.